Department of Orthopedic Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, Republic of Korea.
Department of Orthopedic Surgery, King Abdulaziz Air Base Hospital, Ministry of Defense, 75M2+R7R, King Abdel Aziz Air Base, Dhahran, Saudi Arabia.
J Int Med Res. 2024 Nov;52(11):3000605241291735. doi: 10.1177/03000605241291735.
Intra-articular injections aimed at correcting underlying pathophysiological processes and providing pain relief are essential for managing knee osteoarthritis (KOA). Collagen, the primary component of articular cartilage, has a long half-life, making it a promising candidate for intra-articular injections with a low risk of serious side effects. The first of the two cases in this report involved a woman in her early 70s with a 6-year history of persistent left knee pain. The second case involved a woman in her mid-50 s with a >7-year history of right knee pain. Both patients received hyaluronic acid injections every 6 months, totaling 10 injections over 5 years. They were diagnosed with Kellgren-Lawrence grade 2 KOA. The patients received two 3-mL intra-articular injections of 6% collagen, administered at baseline and 6 months later. Improvements in clinical outcomes, including visual analog scale scores and Western Ontario and McMaster Universities Osteoarthritis Index scores, were observed and maintained in both patients, with no side effects reported. In summary, when collagen injections were administered to these two patients with KOA, clinical improvements lasted approximately 6 months, and repeated treatments demonstrated efficacy and safety similar to the initial course.
关节内注射旨在纠正潜在的病理生理过程并提供疼痛缓解,对于管理膝骨关节炎(KOA)至关重要。胶原是关节软骨的主要成分,具有较长的半衰期,因此作为关节内注射的候选药物具有低严重副作用风险。本报告中的前两个病例涉及一名 70 岁出头的女性,她患有持续的左膝疼痛 6 年。第二个病例涉及一名 50 多岁的女性,她患有右膝疼痛>7 年。两名患者每 6 个月接受一次透明质酸注射,5 年内共进行了 10 次注射。她们被诊断为 Kellgren-Lawrence 分级 2 级 KOA。患者在基线时和 6 个月后各接受了两次 3 毫升的 6%胶原关节内注射。两名患者的临床结局均得到改善,包括视觉模拟评分和西部安大略省和麦克马斯特大学骨关节炎指数评分,且无不良反应报告。总之,当对这两名 KOA 患者进行胶原注射时,临床改善持续了大约 6 个月,重复治疗显示出与初始疗程相似的疗效和安全性。